A phase 1/2 study of LM-302, an anti-claudin 18.2 (CLDN18.2) antibody-drug conjugate in patients with advanced gastric/gastroesophageal junction cancer.
Chunmei Bai(Shanxi Medical University), Jin Li(Hainan Medical University), Heshui Wu(Union Hospital), Yi Zheng(Second Affiliated Hospital of Xi'an Jiaotong University), Fuxiang Zhou(Wuhan University), Rusen Zhao(Central Hospital of Zibo), Yuping Sun(Shandong University), Jinhua Wen(Nanchang University), Jieer Ying(Chinese Academy of Medical Sciences & Peking Union Medical College), Junli Xue(Shanghai East Hospital), Jianping Xiong(Nanchang University), Yanqiao Zhang(Harbin Medical University), Meili Sun(Jinan Central Hospital), Zhihua Gong, Ligang Xing(Affiliated Hospital of Southwest Medical University), Shiwei Guo(Wenzhou Medical University), Zhizhen Zhu, Xiuli Yang(Nanyang Medical College), Lixin Wan(Nanyang Institute of Technology), Yiyi Yu(Sun Yat-sen University)
Cited by 16
Related Papers
Hepatogastroenterology
|Hepatogastroenterology|2012|1.3k
CaMKII is a RIP3 substrate mediating ischemia- and oxidative stress–induced myocardial necroptosis
|Nature Medicine|2016|791
Non-invasive early detection of cancer four years before conventional diagnosis using a blood test
|Nature Communications|2020|641
Genetic evidence supports demic diffusion of Han culture
|Nature|2004|482